Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians
1Columbia University Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
Meeting: 2019 American Transplant Congress
Abstract number: D117
Keywords: Age factors, Hepatocellular carcinoma, Liver transplantation, Survival
Session Information
Session Name: Poster Session D: Liver: Hepatocellular Carcinoma and Other Malignancies
Session Type: Poster Session
Date: Tuesday, June 4, 2019
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: The impact of advanced age on liver transplantation (LT) for hepatocellular carcinoma (HCC) has not been well studied. We sought to compare post-OLT survival and tumor recurrence outcomes of patients older than 70 to younger patients.
*Methods: This is a single-center retrospective cohort study of all consecutive patients with HCC treated with LT between 1998 and 2018. Patient and tumor characteristics as well as post-LT survival and oncologic outcomes were compared among patients older and younger than 70 years.
*Results: A total of 45 patients >70 years were identified and their outcomes compared to 588 patients <70 years. The median follow-up duration for the cohort was 54 months (IQR 23-103). Baseline, preoperative and tumor characteristics were comparable among the two age groups with the only exception of liver disease etiology. While Hepatitis C was the most common etiology for liver disease in both groups, HCV was more common among younger patients (61 vs 44%) while NASH was more prevalent among septuagenarians (20 vs 7%, p=0.034) . Post-LT outcomes were not significantly different between age groups . Patients >70 and <70 had comparable 5-year survival rates of 67 and 71% (p=0.349) respectively and 5-year recurrence-free survival rates of 78 and 86% (p=0.581). Finally, the time to recurrence was not significantly different in the two groups with a median of 13 (IQR 7 - 31) for patients < 70 and 25 months (IQR 16 - 42) for those >70 (p=0.151).
*Conclusions: Advanced age is not associated with worse survival or tumor recurrence outcomes. Selected patients older than 70 should have a fair evaluation for LT for HCC without age being a deciding exclusion factor.
To cite this abstract in AMA style:
Najjar M, Bruestle K, Jiang P, Lieberman E, Hwang R, Mathur A, Verna EC, Griesemer A, Samstein B, Kato T, Saenger YM, Halazun KJ, Emond JC. Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-liver-transplantation-for-hepatocellular-carcinoma-in-septuagenarians/. Accessed December 4, 2024.« Back to 2019 American Transplant Congress